Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 11, 2022

Safety and Efficacy of Ceritinib for Patients With ALK+ NSCLC Metastatic to the Brain and/or Leptomeninges

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Clin. Cancer Res 2022 Jan 28;[EPub Ahead of Print], LQM Chow, F Barlesi, EM Bertino, et al

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading